Clinical trials: Cell Free DNA
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
The trial will enroll up to 47 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00694213
- Testing
- VCL-IPM1, VCL-IPT1, PBS
- Where
- 3 sites in United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Vical
Early Pregnancy Loss
Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss
The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.
- Trial name
- NCT04935138
- Testing
- cfDNA analysis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Quest Diagnostics-Nichols Insitute
Infertility (IVF Patients)
Correlation of the Genetic Constitution of the Spent Blastocyst Media
The main objective of this study is to improve niPGT-A (non-invasive Preimplantation Genetic Testing for Aneuploidies) to avoid the need of a biopsy to perform the genetic analysis of the embryo and to help in understanding the…
- Trial name
- CONNECTED (NCT06780605)
- Testing
- niPGT-A, Multifocal TE biopsies and ICM biopsy
- Where
- 2 sites in Cyprus
- Volunteers
- 230 people
- Sponsor
- Igenomix
Transplant Rejection, Allograft Rejection
Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
This is a multi-center prospective study designed to collect blood samples from transplant patients in order to improve Natera's method for determining allograft rejection status using the donor-derived cell-free DNA analysis…
- Conditions
- Transplant Rejection, Allograft Rejection, Complications
- Trial name
- SPARO (NCT03984747)
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Natera, Inc.
Heart Transplant
Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
This is a prospective, multicenter observational, unblinded, longitudinal cohort study. Subjects will be enrolled into the study prior to or at the time of heart transplantation.
- Trial name
- DEFINE-HT (NCT05309382)
- Testing
- Prospera
- Where
- 9 sites in United States
- Volunteers
- 147 people
- Sponsor
- Natera, Inc.
Gastric Cancer
Post-operative Monitoring of Gastric Cancer
This study is to determine the performance of non-invasive new multi-target biomarkers in the post-operative monitoring of gastric cancer.
- Trial name
- NCT07026240
- Testing
- DNA test
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Suzhou Huhu Health & Technology Inc.
Healthy
A First-in-human Trial to Assess the Safety and Performance of the BioCaptis in Healthy Volunteers
Liquid biopsy is a new field in medicine where doctors can look at small molecules in our blood, called DNA, that carry the genetic material that makes us who we are.
- Trial name
- NCT05813041
- Testing
- BioCaptis
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BioCaptiva Ltd.
Prostate Cancer
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
This clinical study is conducted to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications, especially related to gastrolintestinal (GI) toxicities.
- Trial name
- NCT04580667
- Testing
- Collection of plasma samples
- Where
- 5 sites in United States
- Sponsor
- DiaCarta, Inc.
Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
TR(ACE) Assay Clinical Specimen Study
The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument intended for the measurement of high molecular weight human DNA from plasma as an aid to monitoring disease progression or response to…
- Trial name
- NCT02934360
- Testing
- TR(ACE) Assay Testing
- Where
- 16 sites in United States
- Volunteers
- 450 people
- Sponsor
- Biological Dynamics
Trisomy 21
Non-invasive Chromosomal Examination of Trisomy Study
The purpose of this blinded, multi-center, prospective, case-controlled study is to compare the Ariosa Harmony™ Prenatal Test for trisomy 21 detection with a standard first-trimester prenatal screening test consisting of serum…
- Trial name
- NEXT (NCT01511458)
- Where
- 36 sites in United States, Belgium and 4 more
- Volunteers
- 18,955 people
- Sponsor
- Roche Sequencing Solutions
Rhesus D Genotype
Evaluation of a Noninvasive Fetal RHD Genotyping Test
This study will collect whole blood samples from pregnant subjects who are RhD negative by serology to develop an assay for RHD determination of the fetus.
- Trial name
- IRIS (NCT01054716)
- Where
- 5 sites in United States
- Volunteers
- 500 people
- Sponsor
- Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
- Trial name
- NCT01429389
- Where
- 14 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Sequenom, Inc.
Fetal Complications
Development of a Prenatal Test for Fetal Aneuploidy Detection
This is an observational study to develop and evaluate a blood based prenatal blood test. Pregnant women confirmed to be carrying a fetus with a chromosomal abnormality will be eligible.
- Trial name
- NCT01451671
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Cindy Cisneros
Gastric Cancer
Early Detection and Post-operative Monitoring of Gastric Cancer
This study is to determine the performance of non-invasive new multi-target biomarkers in the early detection and post-operative monitoring of gastric cancer.
- Trial name
- NCT06232395
- Testing
- DNA test
- Where
- 2 sites in China
- Volunteers
- 1,197 people, healthy volunteers welcome
- Sponsor
- Suzhou Huhu Health & Technology Inc.
Kidney Transplant
GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial
The GALACTIC Registry study purpose is to validate the Combination Model-score (CM-score) for increased accuracy in the percentage of the positive predictive value (PPV) of allograft rejection results for the GraftAssure…
- Trial name
- GALACTIC (NCT07551531)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Insight Molecular Diagnostics
NSCLC (Non-small Cell Lung Cancer)
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
This is a multicentre, prospective, study of EGFR )Epidermal Growth Factor Receptor) mutation status in advanced NSCLC (Non-small cell lung cancer)patients (locally advanced and/or metastatic disease) with adenocarcinoma…
- Trial name
- CONCORDANCE (NCT03562819)
- Where
- 14 sites in India
- Volunteers
- 268 people
- Sponsor
- AstraZeneca
Circulating Tumor DNA, Cancer
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has…
- Conditions
- Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing
- Trial name
- NCT02620527
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Foundation Medicine
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in…
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
- Trial name
- NCT03892096
- Testing
- Blood-based cell-free cfDNA qPCR assay
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Cadex Genomics